A Phase 2 Study of Cyclo-Z in Subjects With Type 2 Diabetes
Status:
Completed
Trial end date:
2019-07-15
Target enrollment:
Participant gender:
Summary
This is a double-blind, randomized, placebo-controlled, parallel-group comparison study to
evaluate the efficacy and safety of Cyclo-Z vs. placebo in adult subjects with type 2
diabetes. Approximately 20 clinical sites may be utilized in the United States so that
approximately 300 subjects (a potential 20% screening failure rate) may be screened for total
28-week study period (2 weeks for screening, 24 weeks for treatment, and 2 weeks for safety
follow-up).